Oxford Bioscience Partners

Managing Partner Jonathan J. Fleming and General Partner Dr. Michael Lytton were the longest-serving senior decision-makers, with Fleming representing the firm publicly across multiple fund cycles. The partnership relied on a consensus-driven investment committee structure typical of early-stage life-science venture firms.

Oxford Bioscience Partners functioned as an institutional venture capital firm, raising committed capital from external limited partners across multiple fund vintages. There is no public record of the firm converting to a family office structure or managing exclusively proprietary capital.

The firm pursued a broad venture mandate spanning seed, Series A, and late-stage private rounds, with a historical emphasis on early-stage translational science. It occasionally followed on into crossover rounds when portfolio companies approached public-market readiness.

The firm avoided non-biotech sectors entirely, including consumer internet, enterprise software, and financial technology, maintaining a strict life-science focus across its entire partnership history.

As of 2024, the firm shows no evidence of active fundraising, new deal announcements, or current portfolio activity in press releases or regulatory filings, consistent with a partnership that has ceased active deployment and is managing legacy assets.